OUR FOCUS
Harnessing Transformative Trends
From advanced imaging systems to wearable devices and telemedicine platforms, Medical Technology’s boundaries are blurring with other subsectors to play a central role in improving patient outcomes and healthcare delivery.
Our Medical Technology team supports both emerging and established companies, serving as a valued partner through M&A, capital raising, and strategic transactions.
Recent transactions
$50 Million
Sole Agent
At-the-Market Facility
March 2025
$350 Million
Joint Bookrunner
Rule 144A Convertible Senior Notes Offering
March 2025
$65 Million
Joint Bookrunner
Follow-On
February 2025
$204 Million
Joint Lead Bookrunner
Initial Public Offering
January 2025
Featured Insights
Podcasts
November 2025
Head of the Leerink Center for Pharmacoeconomics, Melanie Whittington, PhD
Featured Research
November 2025
STAT6 of the Union: Competitive Landscape of STAT6-Targeting Therapies
Articles
October 2025
